Dear Reader,

Do you hold any of these AI stocks?

Wall Street insider Jason Bodner — the man who called Nvidia at $4.50 — says today’s AI stocks are about to hit a wall.

And a completely different group of AI firms… names Wall Street is starting to ignore… are about to take off.

This has nothing to do with SpaceX…

A new chatbot…

Autonomous robots…

Or anything you’re likely hearing about.

It has to do with a brand-new “light-speed” device turning AI as we know it into “Accelerated AI”…

Making it 100 times faster…

And 100 times more energy efficient — right here, on Earth.

Already, some of the biggest tech investors like Elon Musk, Mark Zuckerberg, Cathie Wood, and Bill Gates are moving money into it.

Just to name a few…

They’re all moving money to prepare for what’s coming.

But you won’t hear anything about it in the mainstream news…

In fact, TV pundits spent most of this past year talking about AI worries and its “existential risk” to jobs…

Or arguing whether we’re in an AI bubble and when it would pop…

That’s why most Americans won’t see it coming until it’s too late.

Don’t be one of them…

Because if you’re holding the wrong AI stocks when “Accelerated AI” goes mainstream…

You could spend the next decade just trying to claw back to even…

But if you make the one move Jason reveals in this urgent video message…

The next 12 to 24 months could hand you bigger gains than the entire AI boom of the last three years.

Click here to hear the full story and get ahead of the crowd.

But hurry, because this opportunity won’t stay hidden much longer.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

P.S. Jason also shares details on 10 popular AI stocks he says you must dump before this shift goes mainstream. Names sitting in millions of 401(k)s, IRAs, and brokerage accounts. Click here to see if yours made the list.

Insiders Are Betting Big on These 3 Healthcare Stocks

Authored by Thomas Hughes. First Published: 8/31/2026.

Insiders are betting big on pharma in Q3, highlighting opportunities for speculative investors. Speculation is the key word, as these stocks offer risks alongside potentially strong rewards. The question is what is driving insiders’ interest—and how significant the potential gains could be.

Braveheart Bio Boldly Goes Where Few Have Gone Before

Braveheart Bio (NASDAQ: BRVE) is a late-stage biopharmaceutical company that completed its IPO earlier this year. The company’s lead candidate, BHB-1893, is transitioning to Phase 3 trials after positive Phase 2 results and offers substantial upside for investors.

Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.

This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.

Click here to learn this company's name for free today

The therapy targets hypertrophic cardiomyopathy, a segment worth upward of $5 billion in annual sales at peak. Opportunities include disrupting established leaders while penetrating a largely underserved market. Analysts estimate that as few as 20% of eligible patients are currently treated.

Insiders buying this stock include a host of C-suite executives, including the CFO, CDO, and numerous directors, alongside early investors and major shareholders. Their purchases coincided with the IPO and with expanded positions at near-record prices, pushing total insider ownership above 17%.

Institutional ownership remains low because venture capital and private equity firms primarily own the company. The risk is that they sell into any rallies, creating an overhang until market dynamics change. That is likely to happen over the coming quarters, with Phase 3 trials due to begin. However, the real catalyst—the results—is unlikely to arrive until late 2027 at the earliest. Looking ahead, the treatment is undergoing several studies, with results expected over the next two to three years to drive market sentiment, assuming a positive result in the first study.

Analyst coverage is light but reflects an optimistic outlook for the stock. It currently has five ratings, with a consensus Buy rating and about 80% upside. The likely outcome is that the stock trades sideways within its range over the next year, potentially trending lower until signs of traction emerge. While Braveheart’s potential is bright, it is burning through capital and is unlikely to stop doing so within the next 12 to 18 months.

BlossomHill Therapeutics: The Higher-Risk Option

BlossomHill Therapeutics (NASDAQ: BLSM) is a cancer-focused biopharma in a similar position to Braveheart Bio. However, while Braveheart Bio has a candidate entering late-stage trials, BlossomHill Therapeutics does not. Its three candidates are in preclinical or early Phase 1 trials, so the company is still determining whether they are worth advancing. As a result, it has an even longer runway to revenue and profits, though it has a larger end market.

Insiders buying this stock include a similar mix of C-suite executives and directors, including OrbiMed Advisors. OrbiMed Advisors is a global investment firm focused on health care with over $20 billion under management. It acts as a lead investor, investing across the company lifecycle and helping businesses grow into their potential.

Analyst and institutional coverage highlight the stock’s risks. Institutions hold a token 5% of the shares, while no analysts covering BlossomHill are currently tracked. With these factors in play, BLSM shares are ripe for short-selling, sharp corrections, and downtrends, despite the fast-track status achieved by one of its candidates.

Elanco: Pet-Friendly Investment With Robust Pipeline, Growth, and Profits

Elanco (NYSE: ELAN) is not a mainstream health care company, as it focuses on pets and livestock. The business is divided into two operating segments: Companion Animal and Livestock, providing name-brand vaccines, medicines, and technology across both segments. Catalysts in 2026 include a corporate turnaround centered on a robust pipeline. The latest launch has already achieved blockbuster status, and strength is expected to continue as new products launch.

Insiders buying include directors, the CFO, and an executive vice president, extending a trend that has lasted for the past two years. Analysts rate it as a Moderate Buy and show modest conviction, with 13 covering the stock. They have a bullish bias and see the stock rising 20% to the consensus target, highlighting its growth and profit potential.

Unlike BRVE and BLSM, ELAN did not recently go public. This stock has been trading for several years and is in the midst of a price recovery. After a 2023 decline caused by sluggish growth and lackluster prospects, the bottom was hammered out in 2024, and the rebound is now gaining momentum. The consensus price target of $29 would be enough to break the stock out of consolidation and set a new high, opening the door to a larger advance over time.

Elanco’s biggest risks are operational, including foreign exchange changes, product launches, adoption, and regulatory changes. Foreign exchange effects hit results quarterly and can swing from helpful to harmful in a single quarter. Product launches and adoption pose a greater risk because they increase upfront costs and can lead to weaker-than-expected results when delayed, sluggish, or disrupted by competition.